Sera Prognostics Study Finds PreTRM Blood Test Reduces Preterm Births and Newborn Complications

Reuters

Jan 07

<a href="https://laohu8.com/S/SERA">Sera Prognostics</a> Study Finds PreTRM Blood Test Reduces Preterm Births and Newborn Complications

Sera Prognostics Inc. has announced the publication of results from the PRIME Study, a randomized controlled trial evaluating the PreTRM blood test for predicting spontaneous preterm birth in asymptomatic women carrying a single baby. The study, published in the peer-reviewed journal PREGNANCY, involved 5,018 participants and found that early risk screening with the PreTRM Test, combined with targeted interventions, led to 56% and 32% fewer babies born before 32 and 35 weeks, respectively. Additionally, the study reported 20% fewer neonatal intensive care unit (NICU) admissions and a 20% reduction in odds of neonatal morbidity. Results from the PRIME Study will be discussed in detail during a Jefferies fireside chat on January 9, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sera Prognostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA56968) on January 07, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2601480546"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2601480546\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2601480546?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-07 21:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601480546","market":"nz","top_or_hot":-1,"title":"Sera Prognostics Study Finds PreTRM Blood Test Reduces Preterm Births and Newborn Complications","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SERA\">Sera Prognostics</a> Study Finds PreTRM Blood Test Reduces Preterm Births and Newborn Complications\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sera Prognostics Inc. has announced the publication of results from the PRIME Study, a randomized controlled trial evaluating the PreTRM blood test for predicting spontaneous preterm birth in asymptomatic women carrying a single baby. The study, published in the peer-reviewed journal PREGNANCY, involved 5,018 participants and found that early risk screening with the PreTRM Test, combined with targeted interventions, led to 56% and 32% fewer babies born before 32 and 35 weeks, respectively. Additionally, the study reported 20% fewer neonatal intensive care unit (NICU) admissions and a 20% reduction in odds of neonatal morbidity. Results from the PRIME Study will be discussed in detail during a Jefferies fireside chat on January 9, 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sera Prognostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA56968) on January 07, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sera Prognostics Study Finds PreTRM Blood Test Reduces Preterm Births and Newborn Complications</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSera Prognostics Study Finds PreTRM Blood Test Reduces Preterm Births and Newborn Complications\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-07 21:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SERA\">Sera Prognostics</a> Study Finds PreTRM Blood Test Reduces Preterm Births and Newborn Complications\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sera Prognostics Inc. has announced the publication of results from the PRIME Study, a randomized controlled trial evaluating the PreTRM blood test for predicting spontaneous preterm birth in asymptomatic women carrying a single baby. The study, published in the peer-reviewed journal PREGNANCY, involved 5,018 participants and found that early risk screening with the PreTRM Test, combined with targeted interventions, led to 56% and 32% fewer babies born before 32 and 35 weeks, respectively. Additionally, the study reported 20% fewer neonatal intensive care unit (NICU) admissions and a 20% reduction in odds of neonatal morbidity. Results from the PRIME Study will be discussed in detail during a Jefferies fireside chat on January 9, 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sera Prognostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA56968) on January 07, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL8cJRbt:1","article_id":"2601480546","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601480546","pubTimestamp":1767792687,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sera Prognostics Inc. has announced the publication of results from the PRIME Study, a randomized controlled trial evaluating the PreTRM blood test for predicting spontaneous preterm birth in asymptomatic women carrying a single baby. The study, published in the peer-reviewed journal PREGNANCY, involved 5,018 participants and found that early risk screening with the PreTRM Test, combined with targeted interventions, led to 56% and 32% fewer babies born before 32 and 35 weeks, respectively. Additionally, the study reported 20% fewer neonatal intensive care unit  admissions and a 20% reduction in odds of neonatal morbidity. Results from the PRIME Study will be discussed in detail during a Jefferies fireside chat on January 9, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SERA":"Sera Prognostics, Inc.","BK4539":"次新股"},"translate_title":"血清预后研究发现PreTRM血液检测可减少早产和新生儿并发症","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SERA":0.9},"content_text":"Sera Prognostics Study Finds PreTRM Blood Test Reduces Preterm Births and Newborn Complications\n    \n\n        Sera Prognostics Inc. has announced the publication of results from the PRIME Study, a randomized controlled trial evaluating the PreTRM blood test for predicting spontaneous preterm birth in asymptomatic women carrying a single baby. The study, published in the peer-reviewed journal PREGNANCY, involved 5,018 participants and found that early risk screening with the PreTRM Test, combined with targeted interventions, led to 56% and 32% fewer babies born before 32 and 35 weeks, respectively. Additionally, the study reported 20% fewer neonatal intensive care unit (NICU) admissions and a 20% reduction in odds of neonatal morbidity. Results from the PRIME Study will be discussed in detail during a Jefferies fireside chat on January 9, 2026.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sera Prognostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA56968) on January 07, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}